MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 48 filers reported holding MERSANA THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,390,488 | -79.4% | 691,785 | -54.1% | 0.00% | -66.7% |
| Q1 2024 | $6,753,958 | -14.2% | 1,507,580 | -55.6% | 0.00% | 0.0% |
| Q4 2023 | $7,875,101 | +184.8% | 3,394,440 | +55.9% | 0.00% | +200.0% |
| Q3 2023 | $2,765,616 | -60.4% | 2,177,650 | +2.7% | 0.00% | -66.7% |
| Q2 2023 | $6,975,514 | +134484.5% | 2,120,217 | +68.1% | 0.00% | 0.0% |
| Q1 2023 | $5,183 | -75.9% | 1,261,054 | -65.6% | 0.00% | -75.0% |
| Q4 2022 | $21,468 | -99.9% | 3,663,527 | -3.2% | 0.01% | -20.0% |
| Q3 2022 | $25,581,000 | +26.3% | 3,784,175 | -13.7% | 0.02% | +15.4% |
| Q2 2022 | $20,248,000 | +3.9% | 4,382,701 | -10.3% | 0.01% | +30.0% |
| Q1 2022 | $19,486,000 | +392.6% | 4,883,749 | +667.8% | 0.01% | +400.0% |
| Q4 2021 | $3,956,000 | +304.5% | 636,084 | +513.2% | 0.00% | +100.0% |
| Q3 2021 | $978,000 | -77.9% | 103,737 | -68.2% | 0.00% | -66.7% |
| Q2 2021 | $4,429,000 | -4.9% | 326,143 | +13.4% | 0.00% | 0.0% |
| Q1 2021 | $4,655,000 | +142.6% | 287,671 | +299.0% | 0.00% | +200.0% |
| Q4 2020 | $1,919,000 | -33.6% | 72,100 | -53.5% | 0.00% | -66.7% |
| Q3 2020 | $2,890,000 | -84.1% | 155,203 | -80.0% | 0.00% | -88.0% |
| Q2 2020 | $18,180,000 | +507.4% | 776,938 | +51.4% | 0.02% | +257.1% |
| Q1 2020 | $2,993,000 | -35.0% | 513,299 | -36.1% | 0.01% | +16.7% |
| Q4 2019 | $4,604,000 | +6771.6% | 803,541 | +1789.6% | 0.01% | – |
| Q3 2019 | $67,000 | -76.3% | 42,524 | -39.2% | 0.00% | – |
| Q2 2019 | $283,000 | -43.7% | 69,982 | -26.9% | 0.00% | -100.0% |
| Q1 2019 | $503,000 | +177.9% | 95,714 | +116.3% | 0.00% | – |
| Q4 2018 | $181,000 | -95.1% | 44,256 | -88.0% | 0.00% | -100.0% |
| Q3 2018 | $3,697,000 | +68.2% | 369,723 | +200.5% | 0.01% | +66.7% |
| Q2 2018 | $2,198,000 | +130.2% | 123,053 | +122.7% | 0.00% | +200.0% |
| Q3 2017 | $955,000 | +12.0% | 55,256 | -9.5% | 0.00% | -50.0% |
| Q2 2017 | $853,000 | – | 61,029 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $28,503,484 | 2.94% |
| Logos Global Management LP | 2,800,000 | $9,212,000 | 1.25% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,100,000 | $3,619,000 | 1.12% |
| 5AM Venture Management, LLC | 1,305,000 | $4,293,450 | 1.07% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,000,000 | $3,290,000 | 1.02% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $2,975,042 | 0.93% |
| Sarissa Capital Management LP | 2,632,900 | $8,662,241 | 0.86% |
| DAFNA Capital Management LLC | 810,845 | $2,667,680 | 0.73% |
| Tri Locum Partners LP | 428,307 | $1,409,130 | 0.52% |
| Avidity Partners Management LP | 3,790,000 | $12,469,100 | 0.44% |